Colossal Biosciences, the pioneering force in the realm of genetic engineering, has successfully secured an impressive $200 million in funding to further its mission of transforming the future of biodiversity and environmental sustainability. Recognized for being at the forefront of genomic breakthroughs, Colossal harnesses advanced technologies to revolutionize the way we approach extinct species restoration and the conservation of critically endangered species. By applying CRISPR technology to the woolly mammoth鈥攁n iconic symbol of extinction鈥攖he company has set the stage for a new era in which we can effectively repopulate ecosystems crucial for supporting life on our planet. This significant funding will not only enhance Colossal鈥檚 ongoing research and development efforts but will also fuel the expansion of their innovative projects aimed at restoring ecological balance. As the company strives to take on humanity's inherent responsibility of healing the Earth's ecosystems, this investment will empower Colossal to create viable solutions that address pressing environmental challenges and promote sustainable living for future generations. With a commitment to cutting-edge science and an unwavering dedication to the planet, Colossal Biosciences is truly leading the charge in rewriting the narratives of extinction and conservation, ultimately redefining what is possible within the beautiful tapestry of life on Earth.
Colossal Biosciences Secures $200 Million in Series C Funding for Revolutionary Genetic Engineering Innovations
Recently funded 路 $200.0M Series cScience & Technology
Get the full Colossal Biosciences company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
